CRISPR Therapeutics (CRSP)
(Delayed Data from NSDQ)
$48.69 USD
+1.19 (2.51%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $48.55 -0.14 (-0.29%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
CRISPR Therapeutics AG (CRSP) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$83.59 | $199.00 | $30.00 | 75.98% |
Price Target
Based on short-term price targets offered by 22 analysts, the average price target for CRISPR Therapeutics AG comes to $83.59. The forecasts range from a low of $30.00 to a high of $199.00. The average price target represents an increase of 75.98% from the last closing price of $47.50.
Analyst Price Targets (22)
Broker Rating
CRISPR Therapeutics AG currently has an average brokerage recommendation (ABR) of 2.20 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 28 brokerage firms. The current ABR compares to an ABR of 2.20 a month ago based on 28 recommendations.
Of the 28 recommendations deriving the current ABR, 13 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 46.43% and 3.57% of all recommendations. A month ago, Strong Buy made up 46.43%, while Buy represented 3.57%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/CRSP.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 13 | 13 | 13 | 13 | 13 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 11 | 11 | 11 | 11 | 10 |
Sell | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 2 | 2 | 2 | 2 | 2 |
ABR | 2.20 | 2.20 | 2.20 | 2.20 | 2.17 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/12/2024 | Truist Securities | Joon Lee | Strong Buy | Strong Buy |
8/8/2024 | Cantor Fitzgerald & Co | Eric Schmidt | Hold | Hold |
8/6/2024 | William Blair | Sami Corwin | Strong Buy | Strong Buy |
8/6/2024 | Not Identified | Not Identified | Hold | Hold |
8/6/2024 | Evercore Partners | Liisa A Bayko | Hold | Hold |
8/6/2024 | Needham & Company | Gil J Blum | Moderate Buy | Moderate Buy |
8/6/2024 | Not Identified | Not Identified | Hold | Hold |
8/5/2024 | Piper Sandler | Edward A Tenthoff | Strong Buy | Strong Buy |
8/5/2024 | Not Identified | Not Identified | Strong Sell | Strong Sell |
7/24/2024 | Cowen & Co. | Tyler Van Buren | Strong Sell | Strong Sell |
6/30/2024 | Goldman Sachs | Salveen Richter | Hold | Hold |
6/28/2024 | Guggenheim Securities | Debjit Chattopadhyay | Not Available | Hold |
5/28/2024 | Chardan Capital Markets | Yevgeniya Livshits | Strong Buy | Strong Buy |
5/9/2024 | Robert W. Baird & Co. | Jack K Allen | Hold | Hold |
5/9/2024 | Wells Fargo Securities | Yanan Zhu | Hold | Hold |
5/9/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/9/2024 | Not Identified | Not Identified | Hold | Hold |
5/9/2024 | JMP Securities | Silvan C Tuerkcan | Strong Buy | Strong Buy |
5/8/2024 | Brookline Capital Markets | Leah R Cann | Strong Buy | Strong Buy |
4/18/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/12/2024 | SVB Securities | Mani Foroohar | Strong Buy | Strong Buy |
3/5/2024 | Mizuho SecuritiesUSA | Salim Syed | Strong Buy | Strong Buy |
2/15/2024 | Not Identified | Not Identified | Not Available | Hold |
2/8/2024 | Not Identified | Not Identified | Hold | Hold |
12/19/2023 | BMO Capital Markets | Kostas Biliouris | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.20 |
ABR (Last week) | 2.20 |
# of Recs in ABR | 28 |
Average Target Price | $83.59 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 81 of 253 |
Current Quarter EPS Est: | -1.45 |